Allogene Therapeutics Inc (NAS:ALLO)
$ 2.49 0.04 (1.63%) Market Cap: 519.87 Mil Enterprise Value: 223.93 Mil PE Ratio: 0 PB Ratio: 0.92 GF Score: 34/100

Allogene Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 13, 2022 / 08:20PM GMT
Release Date Price: $8.85 (-9.14%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Very good afternoon. Thank you very much for joining us at the Goldman Sachs 2022 Healthcare Conference (inaudible) To start the call, can you highlight the overview (inaudible) the progress in general across the (inaudible) portfolio (inaudible).

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thank you, Salveen. First of all, thanks -- thank you very much for joining us here. (inaudible) Great to see you. (inaudible)

(inaudible) system and as for last 4 years. Finally, at the company, it's really based on taking the allogeneic assets from Pfizer (inaudible) patient platform that's based on ALLO-647, our anti-CD52 antibody, and generating the proof of concept.

The proof of concept here really is not only getting the deep responses but also demonstrating the durability of the response. So probably a highlight coming from our most advanced program, ALLO-501A, which we are planning to initiate the pivotal study. Relatively soon,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot